All In Biotech

Drug Trial Radar · NCT07023835

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Usnoflast Administered to Adult Subjects With ALS

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Sep 17, 2025

Primary completion

Mar 2028

Study completion Oct 2028

Sponsor

Lead sponsor
Zydus Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

  • 50 mg UsnoflastDrug

    50 mg Usnoflast (50 mg Usnoflast capsules and matching placebo of 25 mg capsule)

  • 75 mg UsnoflastDrug

    75 mg Usnoflast (25 mg + 50 mg Usnoflast capsules)

  • PlaceboDrug

    Matching placebo of 25 mg and 50 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of Usnoflast versus placebo assessed using the revised ALSFRS-R total scoreTime frame: From baseline through Week 36
  2. Efficacy of Usnoflast versus placebo assessed using the survivalTime frame: From baseline through Week 36
  3. Effect of Usnoflast versus placebo on survival in Open label extension phaseTime frame: From baseline through Week 16
  4. Number of participants with treatment emergent adverse events in open label extensionTime frame: From baseline through Week 16
  5. Number of participants with Serious adverse events in open label extensionTime frame: From baseline through Week 16

Locations

49 sites in 12 countries. Site status is shown where the registry gives one.

  • Zydus US015

    La Jolla, California · Recruiting

  • Zydus US008

    Orange, California · Not yet recruiting

  • Zydus US013

    San Francisco, California · Recruiting

  • Zydus US005

    New Britain, Connecticut · Recruiting

  • Zydus US012

    Tampa, Florida · Recruiting

  • Zydus US007

    Atlanta, Georgia · Recruiting

  • Zydus US010

    Boston, Massachusetts · Recruiting

  • Zydus US006

    Detroit, Michigan · Recruiting

  • Zydus US014

    Lincoln, Nebraska · Recruiting

  • Zydus US003

    Winston-Salem, North Carolina · Recruiting

  • Zydus US009

    Pittsburgh, Pennsylvania · Recruiting

  • Zydus US001

    Dallas, Texas · Recruiting

  • Zydus US002

    Houston, Texas · Recruiting

  • Zydus US004

    Richmond, Virginia · Recruiting

  • Zydus US011

    Seattle, Washington · Recruiting

  • Zydus 202

    Southport, Australia · Not yet recruiting

  • Zydus 200

    Caulfield South, Australia, Australia · Recruiting

  • Zydus 201

    Sydney, New South Wales, Australia · Recruiting

  • Zydus 110

    Leuven, Belgium, Belgium · Not yet recruiting

  • Zydus 101

    Toronto, Ontario, Canada · Not yet recruiting

  • Zydus 100

    Québec, Quebec, Canada · Active not recruiting

  • Zydus 124

    Clermont-Ferrand, France, France · Not yet recruiting

  • Zydus 122

    Limoges, France, France · Not yet recruiting

  • Zydus 123

    Montpellier, France, France · Recruiting

  • Zydus 125

    Nice, France, France · Recruiting

  • Zydus 120

    Paris, France, France · Recruiting

  • Zydus 121

    Tours, France, France · Recruiting

  • Zydus 130

    Dresden, Germany, Germany · Not yet recruiting

  • Zydus 133

    Hanover, Germany, Germany · Not yet recruiting

  • Zydus 134

    Jena, Germany, Germany · Not yet recruiting

  • Zydus 131

    Lübeck, Germany, Germany · Not yet recruiting

  • Zydus 132

    Rostock, Germany, Germany · Not yet recruiting

  • Zydus 135

    Ulm, Germany, Germany · Not yet recruiting

  • Zydus 140

    Dublin, Ireland, Ireland · Not yet recruiting

  • Zydus 150

    Brescia, Italy · Recruiting

  • Zydus 154

    Genova, Italy, Italy · Not yet recruiting

  • Zydus 153

    Milan, Italy, Italy · Not yet recruiting

  • Zydus 151

    Modena, Italy, Italy · Not yet recruiting

  • Zydus 152

    Naples, Italy, Italy · Recruiting

  • Zydus 160

    Utrecht, Netherlands, Netherlands · Recruiting

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.